Objectives: Classification of non-small-cell lung cancer (NSCLC) into growth patterns is based on the following question: What does the tumour do with normal lung parenchyma? There are only three possible ways according to which a tumour can behave: (1) preservation of lung tissue and use of its microenvironment for further growth, (2) destruction of lung tissue and formation of new microenvironment for continued expansion and (3) preservation of lung tissue and formation of new microenvironment (modulation). The aim of the current study is to test the prognostic value of growth-pattern classification along with other clinical, pathological and immunohistochemical factors. Methods: Clinicopathological factors of 239 patients operated for NSCLC were retrospectively reviewed. Preoperative smoking status was determined based on two prospectively independent questionnaires. Co-morbidity was determined based on Charlson co-morbidity index (CCI). Haematoxylin-eosin tissue sections were analysed for the determination of tumour growth patterns, histological types, grading, necrosis and desmoplasia. Tumour cell proliferation, endothelial cell proliferation and microvessel density were determined based on double immunostaining with CD34 and Ki67 antibodies. Follow-up data were updated in 2008. Results: According to the growth-pattern classification, 161 patients (67.4%) had a destructive, 33 (13.8%) a papillary and 45 (18.8%) an alveolar growth pattern. Multiple Cox regression analysis showed that older age ( p < 0.001), lymph node metastasis ( p < 0.001), growth-pattern classification ( p = 0.036) and current smokers ( p = 0.027) were independent prognostic factors for overall survival. Similar results were obtained for disease-specific and disease-free survival. Papillary (hazard ratio = 1.658 and confidence interval = 1.001-2.748, p = 0.050) and alveolar (hazard ratio = 2.056 and confidence interval = 1.305-3.237, p = 0.002) growth patterns were independent predictors of early recurrence. Conclusions: Growth-pattern classification remains a significant prognostic factor in NSCLC providing a possible explanation for survival differences in the same disease stage. #
Introduction
One of the true challenges in thoracic oncology is the treatment of lung cancer. Indeed, lung cancer is the leading cancer worldwide whether considered in terms of incidence or mortality [1] . The treatment and prognosis of lung cancer is based on tumour-node-metastasis (TNM) classification [2] . The TNM classification is, in fact, a holistic simplification of anatomic extension of the disease at the time of diagnosis. Although TNM staging gives an accurate estimate of the progression of the disease at the time of diagnosis, it does not always account for survival differences. Resected stage I nonsmall-cell lung cancer (NSCLC) is a typical example with wide differences in survival for tumours resected at an identical early stage.
An important future perspective is the treatment of lung cancer based on the biologic profile of the individual tumour complementary to disease staging. The rationale of a biological classification of NSCLC is twofold; first, to obtain an additional prognostic system complementary to disease staging, which can be easily used in clinical practice, and second, to obtain information about the biological profile of the tumour for individualisation of the patient's treatment [3] .
We have proposed a biologic classification of NSCLC based on holistic simplification of lung cancer biology [4, 5] . The growth-pattern classification is based on the global morphologic characteristics of tumour tissue at the invading front on a haematoxylin-eosin (H&E)-stained section. The growthpattern classification must not be confused with the histological classification of NSCLC. The focus in histology is predominantly on the morphologic characteristics of individual tumour cells, whereby enormous morphologic heterogeneity exists even in different fields of the same tumour section. The focus in growth-pattern classification is the following question: what does the tumour do as a whole with regard to the normal lung parenchyma at the invading front? There are only three possible ways in which a tumour can behave according to this classification: (1) preservation of lung tissue and use of its microenvironment for further growth, (2) destruction of lung tissue and formation of new microenvironment for continued expansion and (3.) preservation of lung tissue and formation of new microenvironment (modulation) (Fig. 1) . We have clearly shown that these growth patterns have an independent prognostic value and represent distinct biologic subtypes with differences in angiogenic and proliferative characteristics [4, 5] . In lung metastases also, we have found the same set of growth patterns [6] .
The aim of this study is to test the prognostic value of growth-pattern classification along with other clinical, pathological and immunohistochemical factors.
Materials and methods

Study population
All relevant clinical information was gathered retrospectively from 239 consecutive patients undergoing curative surgical resection for primary NSCLC at the University Hospital of Antwerp between January 1991 and January 2001. The Institutional Review Board approval and permission was granted prior to data collection and conduction of this study and individual patient consent was waived. All patients were operated on by the same surgeon (PVS) and had survived 30 days beyond the operation. None of the patients had received a systemic therapy or radiotherapy before the curative resection. The patients were followed up every 4 months in the first 2 years, every 6 months from the third year and annually from the sixth year. In every follow-up contact, an interview, physical examination and chest X-ray were performed. The pathological TNM staging was used based on histopathology reports and on the perioperative findings [2] . The tumours were classified according to the current World Health Organization (WHO) histological classification by a pathologist [7] . The end points were death, death from lung cancer and recurrence of the disease based on information gathered from the hospital registry and the medical records. The disease-free interval was defined as the interval between surgery and recurrence. The disease-specific survival was defined as the interval between surgery and death from lung cancer. Recurrence was defined as first radiological sign of local recurrence, metastasis or both, provided that it was substantiated with further clinical progression of the disease and administration of anti-tumoural or palliative therapy, or clear radiological progression or confirmation on biopsy. We have previously published the clinical data of these patients [4, 5] . The follow-up information from previous publication was dated back to January 2003. However, for the current study, the follow-up information of all patients was updated in January 2008.
Previous growth-pattern analysis
H&E-stained tissue sections from all tumour blocks from each patient were examined. Tumours were classified according to growth patterns based on two considerations as described before [4, 5] : first, preservation or destruction of lung parenchyma at the lung-tumour interface (invading front) and, second, presence or absence of a tumourassociated stroma at the lung-tumour interface (Fig. 1) . The interface was defined as a field of Â100 magnification at the edge of the tumour, containing only tumour tissue, next to normal lung tissue. Based on these criteria, tumours were classified into three growth patterns as follows:
(1) Destructive growth pattern: destruction of lung parenchyma with the presence of tumour-associated stroma at the interface (Fig. 1A) . (2) Papillary growth pattern: preservation of the alveolar structure of the lung parenchyma at the interface with formation of stromal stalks containing capillary vessels originating from the alveolar septa, suggesting co-option (the tumour uses the pre-existing vascularisation of the host tissue for the oxygen supply) of alveolar blood vessels with subsequent angiogenesis (Fig. 1B) . (3) Alveolar growth pattern: preservation of the alveolar structure of the lung parenchyma with co-option of septal blood vessels and without evidence of new stroma formation at the interface. In this growth pattern, solid tumour cell nests fill the alveolar spaces, often with the presence of necrosis in the centre of these nests. This group does not include bronchiolo-alveolar carcinoma (BAC), which is characterised by orderly replacement of pneumocytes by tumour cells along the alveolar septa without infiltration, necrosis or fibrovascular proliferation (Fig. 1C) .
Although all tumour blocks were examined, the growth patterns could only be assessed on the tumour blocks on which there was a clear lung-tumour interface. On average 2-3 tumour blocks were available with clear lung-tumour interface based on which the growth pattern was determined. For a tumour to be classified as alveolar or papillary, this tumour growth had to be predominantly (90%) present throughout the whole interface on the different tumour blocks.
In only two cases, a mixed growth pattern was observed at the interface. In these two cases, a major destructive component was always observed with a minor alveolar or papillary component. Therefore, these tumours were included in the destructive group.
Assessment of necrosis
H&E-stained tissue sections from all tumour blocks from each patient were examined for presence of necrosis. The degree of necrosis was determined semi-quantitatively as follows: (1) no necrosis, (2) moderate necrosis, (3) extensive necrosis, but less than 50% of the tumour section and (4) extensive necrosis, more than 50% of the tumour section.
Assessment of tumour desmoplasia
H&E-stained tissue sections from all tumour blocks from each patient were examined for presence of desmoplasia. The degree of desmoplasia was determined semi-quantitatively as follows: (1) no desmoplasia, (2) moderate desmoplasia, (3) extensive desmoplasia, but less than 50% of the tumour section and (4) extensive desmoplasia, more than 50% of the tumour section.
Previous immunohistochemistry
A previous double immunohistochemical technique was used to stain simultaneously, on the one hand, proliferating cells using monoclonal antibodies against Ki-67 antigen (clone No. M 7240, DAKO, Denmark) and, on the other hand, endothelial cells using monoclonal antibodies against CD34 antigen (clone QBEnd 10, DAKO, Denmark), on a Dako Autostainer as described before [5] . Based on this staining, endothelial cell proliferation fraction (ECPF), tumour cell proliferation fraction (TCPF), microvessel density (MVD) and Chalkley count were determined separately at the invading front as well in the centre of the tumours as described before [5] .
Assessment of smoking status
Cigarette-smoking status was determined based on two questionnaires taken prospectively and independently prior to lung operation. In our teaching hospital, every patient has to complete a questionnaire prior to any surgical intervention regarding his/her medical history and tobacco dependence. The first questionnaire contained questions with 'yes' or 'no' answers to determine the smoking status at the time of operation. The questionnaire was self-administered by the patient and reviewed by the nurse for completeness with the patient. The second questionnaire was completed by a medical doctor and consisted of items regarding medical history, complete physical examination and questions about the tobacco dependence of the patient. Both questionnaires were conducted at hospital intake day(s) before surgery. The final cigarette-smoking status was determined based on information from both questionnaires. The patients were classified into four categories based on the cigarette-smoking status at the time of operation: (1) non-smokers, that is, patients who had never smoked, (2) former smokers, that is, patients who had stopped smoking 1 year prior to developing lung cancer, (3) recent quitters, that is, patients who had stopped smoking between diagnosis and operation or within 1 year prior to operation and (4) current smokers, that is, patients who continued smoking.
Assessment of co-morbidity
Information regarding the co-morbid conditions of the patients was based on the two questionnaires taken prospectively and independently prior to lung operation as described above. In addition, a retrospective analysis of the in-patient medical records and the medical records of the relevant consultant respiratory physician was performed, to control and complement the information in both the questionnaires. The co-morbidity was scaled for each patient according to the Charlson co-morbidity index (CCI) [8] . We used a modified CCI validated for operated NSCLC [9] . This modified CCI includes the coronary artery diseases (myocardial infarction, angina, coronary artery bypass graft and percutaneous transluminal coronary angioplasty) and scores it with a value of 1.
Statistical analysis
Survival effects were evaluated using Kaplan-Meier plots, and the differences were assessed by the log-rank test. The association between groups was analysed by the chi-square test for categorical variables. Continuous variables were tested for normality with the Kolmogorov-Smirnov test. The distribution of these factors between groups was assessed by the Kruskal-Wallis as these were not normally distributed.
Potential confounders were entered into a Cox multiple regression model for overall disease-specific and disease-free survival. The model building was guided by the influence of the inclusion of these factors on the regression coefficient. The estimated results were presented as hazard ratios with a 95% confidence interval or with standard error. The analyses were performed with SPSS for Windows (Release 15.0 SPSS Inc., Chicago, IL, USA).
Results
Population characteristics and patient status
The median patient age at the time of the operation was 66 years (range: 39-87 years). According to pathologic TNM staging, 66 patients were in stage IA, 79 patients in stage IB, 11 patients in stage IIA, 52 patients in stage IIB, 11 patients in stage IIIA and 20 patients were in stage IIIB. Forty-three patients received postoperative radiotherapy. None of the patients received any postoperative chemotherapy. The median follow-up of the whole group was 50 months (range: 2-192 months). The median follow-up of survived patients was 97.5 months. Kaplan-Meier survival probability at 5 years for all patients was 49.7% (standard error = 3.3%).
At the time of final evaluation for this study (January 2008), 80 patients were alive (33.5%) of whom 67 were disease-free, 124 (51.9%) had relapsed and 159 (66.5%) had died of whom 112 died from lung cancer.
Growth-pattern analysis
Based upon growth-pattern classification, 161 (67.4%) patients had a tumour with a destructive, 33 (13.8%) with a papillary and 45 (18.8%) with an alveolar growth pattern.
Clinical, biologic and pathologic profile of growth patterns
The association of growth patterns with basic clinical, pathologic, angiogenic and proliferative factors has been Table 1 Association of different clinical factors with growth patterns.
Items
Destructive Table 2 Association of pathologic factors with growth patterns. described before in the same patient group [5] . The association of growth patterns with basic clinical factors and newly determined parameters, namely, smoking status and comorbidity is presented in Table 1 . There are no significant associations between the clinical factors and growth patterns. The association of growth patterns with basic pathologic factors along with newly determined factors, namely necrosis and desmoplasia is presented in Table 2 . The alveolar and Table 3 Univariate survival analysis for overall, disease-specific and disease-free survival.
Factors
Overall destructive growth patterns were present in all the histological types. The papillary growth pattern was exclusively seen in adenocarcinomas. However, adenocarcinomas expressed all three patterns of growth. The tumours of papillary growth patterns were associated with good grading and tumours of alveolar growth patterns were associated with poor grading. The tumours of alveolar growth pattern were associated with the presence of extensive necrosis.
Survival analyses
Univariate survival analyses
The univariate survival analyses of different clinicopathological factors for overall, disease-specific and disease-free survival are presented in Table 3 . Significant factors were age, type of the operation, T status, N status, tumour stage, smoking status, growth patterns and ECPF at the interface. Pneumonectomy, advanced T-status, lymph node metastasis, advanced stage, current smoking status, alveolar growth pattern and a low ECPF were associated with early death, death from lung cancer and recurrence of the disease in univariate analysis.
The Kaplan-Meier survival curves of the different growth patterns for overall, disease-specific and disease-free survival are presented in Figs. 2-4 . Alveolar growth pattern is consistently associated with poor prognosis.
Multiple Cox regression analyses
For overall survival, lymph node metastasis, alveolar growth pattern, current smoking status and advanced age were independent predictors of early mortality. For diseasespecific survival lymph node metastasis, alveolar growth pattern and current smoking status were independent predictors of lung cancer-specific mortality. For disease-free survival, lymph node metastasis, papillary growth pattern, alveolar growth pattern and current smoking status were independent predictors of early local recurrence or/and metastasis (Table 4 ).
Discussion
NSCLC can easily be classified based on morphologic characteristics of the tumour tissue on the invading front on H&E-stained tissue sections. We had deliberately chosen the invading front as it seems to be the most homogeneous region of the tumour. We argued that the invading front is the most active region in the tumour representing the actual tumour growth activity (at the time of sampling), whereas the centre of the tumour probably represents the past as well as the present tumour growth activity providing a more hetero- geneous region. We had previously shown that the invading front of the NSCLC has the highest ECPF, TCPF and MVD. We had also shown that the different growth patterns have distinct morphologic, angiogenic and proliferative characteristics with distinct prognostic value [4, 5] .
Growth-pattern classification is a simplification of lung tumour biology and represents a synthesis of different biologic characteristics. The attractiveness of the growthpattern hypothesis lies in the fact that it probably integrates several distinct molecular mechanisms into a single feature.
The aim of current study was to test the prognostic value of growth-pattern classification along with other clinical, pathological and immunohistochemical factors. We wanted to test whether the growth-pattern classification would still remain a significant independent factor in multivariable model with diverse prognosticators. We updated the followup information of the previously published population and included newly determined clinical and pathologic factors. Co-morbidity and smoking status were included as these factors have been shown to be clinical prognosticators in NSCLC [10] [11] [12] [13] [14] [15] . Desmoplasia, grading and necrosis were included as these factors are prominent pathologic features in the tumour progression. Tumour desmoplasia, described as fibrotic focus, has been shown to be an independent prognostic factor in breast cancer [16] . Desmoplasia has also been shown to be a prognostic factor in NSCLC [17, 18] . Previous determined factors of angiogenesis (ECPF and MVD), proliferation (TCPF) and tumour pathology (histology) were also included in multiple Cox regression analysis. We have shown that the growth-pattern classification remains an independent predictor of poor prognosis along with age, lymph node metastasis and continued smoking.
The explanations regarding the survival differences between growth patterns have been extensively discussed in previous publications [4] [5] [6] . These prognostic differences are mainly due to the fact that growth patterns are distinct in proliferative and angiogenic profiles as shown before [5] .
The histological grading reported in this study was obtained from the available histopathological reports. The histological grading is based on the degree of tumour cell differentiation. The tumour cell differentiation along with histological subtyping is bound to heterogeneity whereby enormous morphologic heterogeneity exists even in different fields of the same tumour section. A challenge in evaluating histological grade is that the present grading system for lung cancer is not standardised. In addition, the inconsistent grading criteria among different pathologists make the evaluation of this factor more difficult. We have found that generally, tumours with a papillary growth pattern are well differentiated, whereas those with an alveolar growth pattern are poorly differentiated. This observation primarily underlines the hypothesis that tumour growth pattern is probably a synthesis of different patho-biological factors, all of which are important in tumour biology, freeing us from the enormous underlying heterogeneity.
The clinical implications of the growth-pattern classification might be profound. We have previously shown that growth patterns represent distinct biologic subtypes implying that different growth patterns could respond differently to specific treatment modalities such as chemotherapy, radiotherapy and anti-angiogenic therapy. Indeed, we had clearly shown that alveolar growth pattern is non-angiogenic [5] implying that it will probably respond less to treatment with anti-angiogenic drugs.
Second, the proposed classification has a strong independent prognostic value. The growth patterns are a possible explanation for differences in survival of patients in the same stage. The patients with early relapse and reduced overall survival are those with an alveolar and papillary growth pattern. These 'at risk' patients may be identified based on the growth pattern and can be intensively followed or treated with high-dose adjuvant therapy.
There are limitations to the current study and its results; this study is of small scale and is retrospective. However, the Dr Sardari Nia: I think the main problem is that if we consider patients in the same disease stage, patients who have the same histology, the same tumour size, you will find differences in prognosis, and the question is why. It's probably because of the differences in biology of the individual tumours. So what we need is a good biological parameter which is a synthesis of differences between the individual tumours. The growth pattern classification in that sense is a very simple classification because it's based on the tumour behaviour at the invading front. If you have a tumour which preserves the lungs, uses the microenvironment of the lung to grow, it is, of course, genetically probably different from a tumour which does precisely the opposite. So the first question, if we classify tumours in such a manner, does it have a prognostic value? Yes, it does. Then we can go further to analyse what are the possibilities and predictions of such a classification.
With regard to lung cancer, I think the problem is patients who are operated in stage I, and if we find the solution to define subgroups with poor prognosis in that group, I think it would be great. With regard to the group with metastasis, of course this is a different story because it's disseminated disease.
Dr Schmid: Which defines the outcome in many patients. In some patients, you have a small tumour and it does not look very invasive, and then 6 months later you have metastatic disease. And I am not sure if you can link local malignant behaviour, if you want to define it like that, with metastatic disease.
Dr Sardari Nia: Actually, there are data, microarray analysis of a wide variety of adenocarcinoma, metastasis, and primary tumour. They have found a gene signature which is actually predictive of malignancy which is found in the metastasis as well as in the primary tumour. In a sense, you can have a local disease and you can actually study the gene expression profile of the local disease, which is predictive of metastasis. It doesn't mean that you have to study only a metastatic disease to find the same gene expression profile.
Dr Schmid: That was my question. Don't we have to do TNM classification and in the future a fingerprint of these genes in the tumour to predict if it has a bad prognosis or a good prognosis and the histology might not be so important?
Dr Sardari Nia: Yes, but that is also the main issue, that we think that the most advances would be at the technical level, but there are many studies on gene expression profiling in lung cancer. Some of these studies try to subclassify beyond the histology, but if you look at these studies, some find 4 subgroups of adenocarcinoma, others 2 subgroups. So there is inconsistency between the findings. If we look at the prognostic data, you will find studies which find dozens of genes associated with poor prognosis, but there is also inconsistency between which genes are associated with poor prognosis between the different studies. So the problem is more analytical in the sense that if you study 40,000 genes, you will always find dozens of genes associated with poor prognosis. That has been done enough. So what we are actually considering, we are starting from a holistic point of view. We postulate that probably on a morphological basis we can find characteristics which could be associated with poor prognosis and define subgroups of non-small cell lung cancer, and we can redefine that with gene expression profiling. So this analysis is based on hypothesis, and gene expression profile analyses are searching for hypotheses. They are analysing a large scale of genes and looking for a dozen of them which would be associated with poor prognosis.
Dr Schmid: That's a very clinical and practical approach. Paul, do you want to comment on your own paper? Dr Van Schil: I don't think Dr Sardari Nia understood what you were asking, but, in fact, we just received a grant from the Flemish League Against Cancer to look at molecular genetic analysis of those different growth patterns in more detail. Dr Sardari Nia also did specific studies looking at growth patterns in metastatic disease as we are very interested in lung metastases also. Maybe you can comment on that, Peyman.
Dr Sardari Nia: At the start, we found the same features among the lung metastases. For example, lung metastases of renal cell carcinoma, they are very hypervascular tumours. So you have some metastases which are an exact copy of the primary tumour, so destructive, and they make their own stroma, and you have metastases which, like the alveolar growth pattern, are using the microenvironment of the lung for growth.
Dr Schmid: The old question, if a metastasis has mutations that were not in the primary tumour or if the metastasis is an exact copy and the information for invasion and implantation is already there in the primary tumour . . . this is a very long discussion.
Dr R. Milton (Leeds, United Kingdom): I really enjoyed your presentation. I think it's a very important contribution. But presumably, as you had just been talking about before, the growth-pattern classification is just a surrogate way of assessing some sort of gene expression, whatever that gene is. One tumour may exhibit different growth patterns, and that's going to be dependent on the pathologist who is interpreting the histology. Have you found that in your specimens?
Dr Sardari Nia: You mean is there any association with histopathological type? Dr Milton: Yes. A specimen may exhibit different growth patterns within the same specimen.
Dr Sardari Nia: We have to look into that. First of all, all the patients exhibited the same growth pattern. Growth-pattern classification is based on the morphology of the invading front, not the whole tumour specimen. We hypothesised that the invading front would have the largest biological activity, because if you look at the slides, you look at a moment frozen in time, so if you consider the invading front to have the highest biological activity, you are looking at the present, whereas in the centre of the tumour, you are looking at modification of the past and the present, so you have more heterogeneity in the centre of the tumour. So the interface, the invading front, has more homogeneous morphology, and that's why we classified tumours based on the characteristics of the invading front.
Dr A. Khan (Southampton, United Kingdom): If you are faced with a patient with a stage IB tumour, do you envision a future where based on the basis of the growth pattern at the periphery, you can send some patients for adjuvant chemotherapy to affect the long-term prognosis?
Dr Sardari Nia: I think if you validate in a large confirmational study that indeed, for example, alveolar growth pattern is associated with very poor prognosis, you have to follow patients with alveolar growth pattern more intensively or you have to give them adjuvant chemotherapy.
Dr Van Schil: Probably what was not very clear, too, and which was also a surprise to us is that an alveolar growth pattern which is non-angiogenic, has a very poor prognosis. This implies that angiogenesis inhibitors will not be very effective in these patients and other adjuvant therapies will have to be applied.
